Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 641

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 641
---
 |    ​ | ​ | 2024 | ​ | ​ | ​ |         ​ | ​ | 478,400 | ​ | ​ | ​ |                  ​ | ​ | 117,800 | ​ | ​ | ​ |                                          ​ | ​ | — | ​ | ​ | ​ |                           ​ | ​ | 11,079 | ​ | ​ | ​ |         ​ | ​ |   607,279 | ​ | ​ |
| ​                                                                          | ​ | ​ | 2023 | ​ |    ​ | ​ | ​ | ​ |   478,400 | ​ |       ​ | ​ | ​ | ​ |            573,156 | ​ |       ​ | ​ | ​ | ​ |                                    181,792 | ​ | ​ | ​ | ​ | ​ |                      10,509 | ​ |      ​ | ​ | ​ | ​ | 1,243,857 | ​ |         ​ |   |   |
| Scott Terrillion﻿(4)General Counsel, Secretary andChief Compliance Officer | ​ | ​ |    ​ | ​ | 2024 | ​ | ​ | ​ |         ​ | ​ | 463,840 | ​ | ​ | ​ |                  ​ | ​ | 117,800 | ​ | ​ | ​ |                                          ​ | ​ | — | ​ | ​ | ​ |                           ​ | ​ | 11,217 | ​ | ​ | ​ |         ​ | ​ |   592,857 | ​ | ​ |

(1) Amounts reflect the grant date fair value of each option award granted, calculated in accordance with ASC 718. The amounts reflected for 2024 consist of stock options that contained performance conditions and assumes achievement of full performance and excludes the effect of forfeitures. See Performance-based Stock Options below. All of the option awards reported in the table above were granted under Cara’s 2014 Plan and had a term of ten years from the date of grant. The assumptions Cara uses in

367

TABLE OF CONTENTS

calculating the grant date fair value of stock options are substantially similar to those set forth in Note 15 to Cara’s unaudited condensed financial statements for the quarter ended September 30, 2024 included elsewhere in this proxy statement/prospectus. This amount does not reflect dollar amounts actually received by the executive officer or the economic value that may be received by the executive officer upon stock option exercise or any sale of the underlying shares of common stock. The performance conditions of the